Leha, Andreas

[["dc.bibliographiccitation.firstpage","104677"],["dc.bibliographiccitation.journal","Neurobiology of Disease"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Michalke, Bernhard"],["dc.contributor.author","Willkommen, Desiree"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Schulte, Claudia"],["dc.contributor.author","Tönges, Lars"],["dc.contributor.author","Mollenhauer, Brit"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Rückamp, Daniel"],["dc.contributor.author","Börger, Matthias"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2020-12-10T15:20:25Z"],["dc.date.available","2020-12-10T15:20:25Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.nbd.2019.104677"],["dc.identifier.issn","0969-9961"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72661"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","342"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Neurochemistry"],["dc.bibliographiccitation.lastpage","351"],["dc.bibliographiccitation.volume","145"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Michalke, Bernhard"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Boerger, Matthias"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Koch, Jan-Christoph"],["dc.contributor.author","Tönges, Lars"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2018-04-23T11:46:57Z"],["dc.date.available","2018-04-23T11:46:57Z"],["dc.date.issued","2018"],["dc.description.abstract","The diagnosis of Parkinson's disease (PD) still lacks objective diagnostic markers independent of clinical criteria. Cerebrospinal fluid (CSF) samples from 36 PD and 42 age‐matched control patients were subjected to inductively coupled plasma‐sector field mass spectrometry and a total of 28 different elements were quantified. Different machine learning algorithms were applied to the dataset to identify a discriminating set of elements yielding a novel biomarker signature. Using 19 stably detected elements, the extreme gradient tree boosting model showed the best performance in the discrimination of PD and control patients with high specificity and sensitivity (78.6% and 83.3%, respectively), re‐classifying the training data to 100%. The 10 times 10‐fold cross‐validation yielded a good area under the receiver operating characteristic curve of 0.83. Arsenic, magnesium, and selenium all showed significantly higher mean CSF levels in the PD group compared to the control group (p = 0.01, p = 0.04, and p = 0.03). Reducing the number of elements to a discriminating minimum, we identified an elemental cluster (Se, Fe, As, Ni, Mg, Sr), which most importantly contributed to the sample discrimination. Selenium was identified as the element with the highest impact within this cluster directly followed by iron. After prospective validation, this elemental fingerprint in the CSF could have the potential to be used as independent biomarker for the diagnosis of PD. Next to their value as a biomarker, these data also argue for a prominent role of these highly discriminating six elements in the pathogenesis of PD."],["dc.identifier.doi","10.1111/jnc.14316"],["dc.identifier.gro","3142063"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13277"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","0022-3042"],["dc.title","Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.journal","Parkinsonism & Related Disorders"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","63"],["dc.contributor.author","Boerger, Matthias"],["dc.contributor.author","Funke, Sebastian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Roser, Anna-Elisa"],["dc.contributor.author","Wuestemann, Ann-Katrin"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Grus, Franz"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2020-12-10T15:20:41Z"],["dc.date.available","2020-12-10T15:20:41Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.parkreldis.2019.03.001"],["dc.identifier.issn","1353-8020"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72763"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson's disease – A pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Maier, Ilko L."],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Badr, Mostafa"],["dc.contributor.author","Allam, Ibrahim"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Jamous, Ala"],["dc.contributor.author","Hesse, Amelie"],["dc.contributor.author","Psychogios, Marios-Nikos"],["dc.contributor.author","Behme, Daniel"],["dc.contributor.author","Liman, Jan"],["dc.date.accessioned","2021-08-12T07:45:45Z"],["dc.date.available","2021-08-12T07:45:45Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Endovascular treatment (EVT) for large vessel occlusion stroke (LVOS) is highly effective. To date, it remains controversial if intravenous thrombolysis (IVT) prior to EVT is superior compared with EVT alone. The aim of our study was to specifically address the question, whether bridging IVT directly prior to EVT has additional positive effects on reperfusion times, successful reperfusion, and functional outcomes compared with EVT alone. Methods: Patients with LVOS in the anterior circulation eligible for EVT with and without prior IVT and direct admission to endovascular centers (mothership) were included in this multicentric, retrospective study. Patient data was derived from the German Stroke Registry (an open, multicenter, and prospective observational study). Outcome parameters included groin-to-reperfusion time, successful reperfusion [defined as a Thrombolysis in Cerebral Infarction (TICI) scale 2b-3], change in National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), and mortality at 90 days. Results: Of the 881 included mothership patients with anterior circulation LVOS, 486 (55.2%) received bridging therapy with i.v.-rtPA prior to EVT, and 395 (44.8%) received EVT alone. Adjusted, multivariate linear mixed effect models revealed no difference in groin-to-reperfusion time between the groups (48 ± 36 vs. 49 ± 34 min; p = 0.299). Rates of successful reperfusion (TICI ≥ 2b) were higher in patients with bridging IVT (fixed effects estimate 0.410, 95% CI, 0.070; 0.750, p = 0.018). There was a trend toward a higher improvement in the NIHSS during hospitalization [ΔNIHSS: bridging-IVT group 8 (IQR, 9.8) vs. 4 (IQR 11) points in the EVT alone group; fixed effects estimate 1.370, 95% CI, −0.490; 3.240, p = 0.149]. mRS at 90 days follow-up was lower in the bridging IVT group [3 (IQR, 4) vs. 4 (IQR, 4); fixed effects estimate −0.350, 95% CI, −0.680; −0.010, p = 0.041]. There was a non-significantly lower 90 day mortality in the bridging IVT group compared with the EVT alone group (22.4% vs. 33.6%; fixed effects estimate 0.980, 95% CI −0.610; 2.580, p = 0.351). Rates of any intracerebral hemorrhage did not differ between both groups (4.1% vs. 3.8%, p = 0.864). Conclusions: This study provides evidence that bridging IVT might improve rates of successful reperfusion and long-term functional outcome in mothership patients with anterior circulation LVOS eligible for EVT."],["dc.description.abstract","Background: Endovascular treatment (EVT) for large vessel occlusion stroke (LVOS) is highly effective. To date, it remains controversial if intravenous thrombolysis (IVT) prior to EVT is superior compared with EVT alone. The aim of our study was to specifically address the question, whether bridging IVT directly prior to EVT has additional positive effects on reperfusion times, successful reperfusion, and functional outcomes compared with EVT alone. Methods: Patients with LVOS in the anterior circulation eligible for EVT with and without prior IVT and direct admission to endovascular centers (mothership) were included in this multicentric, retrospective study. Patient data was derived from the German Stroke Registry (an open, multicenter, and prospective observational study). Outcome parameters included groin-to-reperfusion time, successful reperfusion [defined as a Thrombolysis in Cerebral Infarction (TICI) scale 2b-3], change in National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), and mortality at 90 days. Results: Of the 881 included mothership patients with anterior circulation LVOS, 486 (55.2%) received bridging therapy with i.v.-rtPA prior to EVT, and 395 (44.8%) received EVT alone. Adjusted, multivariate linear mixed effect models revealed no difference in groin-to-reperfusion time between the groups (48 ± 36 vs. 49 ± 34 min; p = 0.299). Rates of successful reperfusion (TICI ≥ 2b) were higher in patients with bridging IVT (fixed effects estimate 0.410, 95% CI, 0.070; 0.750, p = 0.018). There was a trend toward a higher improvement in the NIHSS during hospitalization [ΔNIHSS: bridging-IVT group 8 (IQR, 9.8) vs. 4 (IQR 11) points in the EVT alone group; fixed effects estimate 1.370, 95% CI, −0.490; 3.240, p = 0.149]. mRS at 90 days follow-up was lower in the bridging IVT group [3 (IQR, 4) vs. 4 (IQR, 4); fixed effects estimate −0.350, 95% CI, −0.680; −0.010, p = 0.041]. There was a non-significantly lower 90 day mortality in the bridging IVT group compared with the EVT alone group (22.4% vs. 33.6%; fixed effects estimate 0.980, 95% CI −0.610; 2.580, p = 0.351). Rates of any intracerebral hemorrhage did not differ between both groups (4.1% vs. 3.8%, p = 0.864). Conclusions: This study provides evidence that bridging IVT might improve rates of successful reperfusion and long-term functional outcome in mothership patients with anterior circulation LVOS eligible for EVT."],["dc.identifier.doi","10.3389/fneur.2021.649108"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88544"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-2295"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Inhouse Bridging Thrombolysis Is Associated With Improved Functional Outcome in Patients With Large Vessel Occlusion Stroke: Findings From the German Stroke Registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Maass, Fabian; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Hermann, Peter; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Varges, Daniela; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Nuhn, Sabine; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","van Riesen, Christoph; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Jamous, Ala; 3Department of Neuroradiology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Focke, Niels K.; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Hewitt, Manuel; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Leha, Andreas; 4Department of Medical Statistics, University Medical Center, Göttingen, Germany"],["dc.contributor.affiliation","Bähr, Mathias; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Zerr, Inga; 1Department of Neurology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Hermann, Peter"],["dc.contributor.author","Varges, Daniela"],["dc.contributor.author","Nuhn, Sabine"],["dc.contributor.author","van Riesen, Christoph"],["dc.contributor.author","Jamous, Ala"],["dc.contributor.author","Focke, Niels K."],["dc.contributor.author","Hewitt, Manuel"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2022-08-04T08:31:14Z"],["dc.date.available","2022-08-04T08:31:14Z"],["dc.date.issued","2022-07-19"],["dc.date.updated","2022-08-02T14:39:19Z"],["dc.description.abstract","The objective of the study was to characterize the pattern of cognitive dysfunction in patients with multiple system atrophy (MSA) applying a standardized neuropsychological assessment. A total of 20 patients with the diagnosis of probable or possible MSA were enrolled for neuropsychological assessment applying the CERAD plus battery. All patients were tested at baseline and 14/20 patients received additional follow-up assessments (median follow-up of 24 months). Additionally, relationship between cortical thickness values/subcortical gray matter volumes and CERAD subitems was evaluated at baseline in a subgroup of 13/20 patients. Trail Making Test (TMT) was the most sensitive CERAD item at baseline with abnormal performance (z-score < −1.28) in one or both pathological TMT items (TMT-A, TMT-B) in 60% of patients with MSA. Additionally, there was a significant inverse correlation between the volume of the left and the right accumbens area and the TMT A item after adjusting for age (left side: p = 0.0009; right side p = 0.003). Comparing both subtypes, patients with MSA-C had significant lower values in phonemic verbal fluency (p = 0.04) and a trend for lower values in semantic verbal fluency (p = 0.06) compared to MSA-P. Additionally, patients with MSA-C showed significantly worse performance in the TMT-B task (p = 0.04) and a trend for worse performance in the TMT-A task (p = 0.06). Concerning longitudinal follow-up, a significant worsening in the TMT-B (p = 0.03) can be reported in MSA. In conclusion, frontal-executive dysfunction presents the hallmark of cognitive impairment in MSA."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fneur.2022.881369"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112628"],["dc.language.iso","en"],["dc.relation.eissn","1664-2295"],["dc.rights","CC BY 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Maass, Fabian"],["dc.contributor.author","Rikker, Sebastian"],["dc.contributor.author","Dambeck, Vivian"],["dc.contributor.author","Warth, Carmina"],["dc.contributor.author","Tatenhorst, Lars"],["dc.contributor.author","Csoti, Ilona"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2021-04-14T08:25:46Z"],["dc.date.available","2021-04-14T08:25:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41598-020-65503-1"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81725"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2045-2322"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]